Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Crinetics Pharmaceuticals Inc
CRNX | US
38.22
USD-0.01
-0.03%
CRNX | US
About Crinetics Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
38.22
Open
38.24
High
39.25
Low
37.75
Crinetics Pharmaceuticals Inc. a clinical stage pharmaceutical company focuses on the discovery development and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777 an oral selective nonpeptide somatostatin type 5 receptor agonist which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894 an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego California.
View LessCRNX | US
Risk
41.9
Sharpe
0.12
Luna's Score
43/100
Recommendation
Sell
Luna says (CRNX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
33.0%1 month
41.9%3 months
52.5%6 months
63.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
6.40
Debt to equity
0.06
Debt to assets
0.06
Ent. to EBITDA
-13.40
Ent. to rev.
3.26K
PEG
-
Other Fundamentals
EBITDA
-276.18M
MarketCap
3.44B
MarketCap(USD)
3.44B
Div. yield
-
Op. margin
-20.75K
Erngs. growth
-
Rev. growth
-59.60
Ret. on equity
-47.66
Short ratio
10.65
Short perc.
8.65
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
7.58
Range1M
10.96
Range3M
20.37
Volumes: Market Activity
Rel. volume
1.23
Price X volume
47.31M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -13.40 | 0.53 | Cheaper |
| Ent. to Revenue | 3,256.73 | 3,967.00 | Par |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.40 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 52.52 | 72.80 | Lower Risk |
| Debt to Equity | 0.06 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 3.44B | 3.66B | Par |
